Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 17/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4282308 | 0.92 | AOC3 (0.68) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| Carbamic Acid SCHEMBL4986143 | 0.91 | AOC3 (0.69) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL6196677 | 0.88 | AOC3 (0.69) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3935576 | 0.87 | AOC3 (0.73) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| Hydrochloric Acid SCHEMBL6387559 | 0.86 | AOC3 (0.57) | AOC3 | |
| SCHEMBL4873920 | 0.86 | AOC3 (0.72) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3931455 | 0.86 | AOC3 (0.77) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4883897 | 0.86 | AOC3 (0.77) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL14019612 | 0.85 | AOC3 (0.71) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1443560 | 0.85 | AOC3 (0.74) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170770-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP 1) INHIBITOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-07-02 | — | — | US | disclosed |
| EP-1737450-A1 | AQUEOUS COMPOSITION COMPRISING THIAZOLE DERIVATIVE | R-Tech Ueno, Ltd. (JP) | 2007-01-03 | — | — | EP | disclosed |
| EP-1608365-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | Sucampo AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005089755-A1 | AQUEOUS COMPOSITION COMPRISING THIAZOLE DERIVATIVE | R-TECH UENO, LTD. (JP) | 2005-09-29 | — | — | WO | disclosed |
| WO-2004087138-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170770-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP 1) INHIBITOR | VCAM1, VAPB, FLT1 | AOC3 402/4885PIK3CD 2212/4885PIK3CA 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.